Amarin lays off US salesforce, names new CEO in shakeup

The new crew in charge at Amarin has outlined their plans to turn things around — and it involves a sweeping reorg.

Amarin will cut all US sales positions and 30% of non-sales roles, while retaining a limited team to support Vascepa, its pharmaceutical-grade fish oil derivative. Instead, it will focus on reaching more patients in Europe (where the drug is marketed as Vazkepa) as well as other international markets. Patrick Holt is stepping in as president and CEO, replacing interim chief Aaron Berg, who will stay on as EVP and president in the US.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

FDA greenlights first over-the-counter birth control pill –

The approval comes after continued calls from women’s health charities in the US to make birth control available over the counter. Image credit: Shutterstock/Gorodenkoff Women

July 13, 2023

New class of antibody could benefit patients with treatment-resistant cancers

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments

July 28, 2023

The Delisting Risk

You’re reading this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight

April 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.